About Genomenon
Genomenon is a Healthcare company based in Ann Arbor (United States) founded in 2014. AI-based bioinformatics tools and genomic variants meta-database are developed. It operates in the Healthcare and Technology sectors. Genomenon has raised $42.87 million across 14 funding rounds from investors including NIH, University of Michigan and HHS. Genomenon has completed 1 acquisition, including Boston Genetics. Its website genomenon.com draws about 27 thousand monthly visits. Genomenon offers products and services including Mastermind, Cancer Knowledgebase, and Curation Services. Its focus areas include Enterprise Applications, Data as a Service, Industries and Healthcare Data. Its legal entity is Genomenon, Inc. Its competitors include Human Longevity, Denali Therapeutics and DNAnexus; 3 of its 3 listed competitors have raised funding.
Company details
Genomenon was founded in 2014 in Ann Arbor, United States, within the bioinformatics sector. AI-driven tools and a comprehensive meta-database of genomic variants are provided for genomic analysis. MASTERMIND organizes variants into clinical categories based on disease associations determined by automated algorithms. SAVANT identifies actionable genetic variants from gene panels, exomes, or patient genomes. PRODIGY analyzes multi-sample datasets to pinpoint disease-causing variants for research purposes.
- Headquarters Ann Arbor, United States
- SectorsHealthcareTechnology
- Email••••••••
- Website genomenon.com
- Social LinkedIn X YouTube
- Legal Name Genomenon, Inc.
- Total Equity Funding$42.87M (USD)
in 14 rounds
- Latest Funding Round$6.03M (USD), Series C
Jul 2026
- InvestorsNIH
& 18 more
- Investments & Acquisitions
Products & Services of Genomenon
Genomenon offers a comprehensive portfolio of products and services, including Mastermind, Cancer Knowledgebase, and Curation Services.
AI tool for analyzing and interpreting genomic datasets.
Platform connecting cancer variants to therapies and trials.
Expert services for variant classification and analysis.
Apps and channels of Genomenon
its YouTube channel Genomenon has 675 subscribers and 30 videos.
Videos from Genomenon
The most watched videos on Genomenon's YouTube channel, Genomenon (675 subscribers). Click a video to play it here.
More on Genomenon.
Funding Insights of Genomenon
Genomenon has successfully raised a total of $42.87M across 14 strategic funding rounds. The most recent funding activity was a Series C round of $6.03 million completed in July 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $42.87M
- Total Rounds 14
- Last Round Series C — $6.03M
- First Round $446,003
(Aug 2015)
- Investors Count 19
Latest 10 of 14 funding rounds of Genomenon with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2026 | $6.03M | Series C | – | – | – |
| May 2024 | $5.46M | Series B | – | – | – |
| Mar 2022 | $20M | Series B | – | Beringea, Spring Mountain Capital | |
| Feb 2022 | $1.7M | Grant | – | – | |
| Mar 2021 | $5.3M | Series B | – | Broadoak Capital Partners, Green Park & Golf Ventures | |
| Oct 2020 | Series A | – | Michigan Rise | – | |
| May 2020 | $2.89M | Series A | – | – | – |
| May 2019 | $1.86M | Grant | – | – | |
| Jan 2019 | $2.5M | Series A | – | IrishAngels | |
| Feb 2017 | $1.71M | Grant | – | – |
19 investors in total: 18 institutional and 1 angel.
Investors in Genomenon
Genomenon has secured backing from 19 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include NIH, University of Michigan and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made in growth-stage startups by Beringea. | beringea.com | Farmington Hills, United States | ||
Venture capital fund focused on multiple sectors | smcgrowthcapital.com | New York, United States | ||
Early-stage venture capital investments are made in medical startups. | 2011 | gpgventures.com | Dallas, United States | |
Angel investments are made in Cloud, SaaS, and manufacturing sectors. | 2012 | irishangels.com | Chicago, United States | |
Seed-focused venture capital firm investing in tech-based startups | investdetroit.com | Detroit, United States | ||
| redcedarcv.com | ||||
Early-stage funding is provided for Michigan-based technology startups. | michiganrise.com | East Lansing, United States | ||
Early-stage company funding is facilitated in Michigan. | miangelfund.com | Ann Arbor, United States | ||
Riverine Ventures is focused on life science and healthcare investments. | riverine.ventures | Sausalito, United States | ||
| redcedarventures.com |
Investor details for Genomenon
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Genomenon
17 people are tracked at Genomenon (7 in leadership, 1 in board & advisors, 9 in team).
| Name | Role | Group |
|---|---|---|
Jon Murray | VP, Sales | Leadership |
Mike Klein | Chief Executive Officer | Leadership |
Anna McGill | Director | Leadership |
Brian Groark | Chief Financial Officer | Leadership |
Sam Globus | VP, Operations | Leadership |
Jonathan Eads | VP, Engineering | Leadership |
Erin McCann | Head Of People | Leadership |
Megan Lim | Co-Founder & Advisor | Board & advisors |
Ajla Doljančić | Senior People Generalist/assoc HRBP | Team |
Gavin Horn | Controller | Team |
Katherine Roberto | Revenue Operations Manager | Team |
Betty Mathias | Project Manager | Team |
Jane B. | Project Manager | Team |
Stephanie Mercurio | Project Manager | Team |
Alexis Taylor | Senior People Generalist/ Associate HRBP | Team |
Mirela Tica-Spahic | Project & Office Manager | Team |
Marty Harris | Fp&a Manager | Team |
Complete people profiles for Genomenon
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Genomenon
Genomenon has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Boston Genetics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Gene therapy-based drug development services are provided. | bostongen.com | Cambridge, United States | 2019 | Jun 2023 | •••• |
Complete acquisition details for Genomenon
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Genomenon
4 dated milestones of Genomenon across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Genomenon is founded.
- Funding First funding round of $446K.
- Acquisition Acquires Boston Genetics.
- Funding Latest funding round, Series C, of $6.0M.
Competitors of Genomenon
Genomenon has 3 listed competitors in our database, 3 of them funded. They include Human Longevity, Denali Therapeutics and DNAnexus.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| humanlongevity.com | 2013 | San Diego, United States | $376.72M | 83 | Genomics data and cell therapy-based diagnostic and therapeutic solutions | |
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| dnanexus.com | 2009 | Mountain View, United States | $472.55M | 143 | Cloud-based genome informatics and data management are provided. |
Detailed competitors of Genomenon
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Genomenon
The website of Genomenon (genomenon.com) receives about 26.7K visits a month.
- Monthly visits26.7K
▼ 18.6% vs previous month
Websites whose visitors overlap most with Genomenon. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
myeloma.ca | myeloma.ca | 100% | #1,269,643 | – | |
oncokb.org | oncokb.org | 97% | #619,220 | – | |
mycancergenome.org | mycancergenome.org | 90% | #1,118,691 | – | |
| insideprecisionmedicine.com | 83% | #507,293 | View details | ||
| smartpatients.com | 83% | 44.2K | #655,452 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for Genomenon
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Clinical Genomics
3 companies that operate in the same segment as Genomenon (Clinical Genomics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Genomenon
Complete news archive for Genomenon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genomenon
Genomenon was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Genomenon is headquartered in Ann Arbor, United States. It is registered at Ann Arbor, Michigan, United States.
Genomenon is a funded company, having raised a total of $42.87M across 14 funding rounds to date. The company's 1st funding round was a Grant of $1.71M, raised on Aug 2015.
Genomenon was founded in 2014 in Ann Arbor, United States, within the bioinformatics sector. AI-driven tools and a comprehensive meta-database of genomic variants are provided for genomic analysis. MASTERMIND organizes variants into clinical categories based on disease associations determined by automated algorithms. SAVANT identifies actionable genetic variants from gene panels, exomes, or patient genomes. PRODIGY analyzes multi-sample datasets to pinpoint disease-causing variants for research purposes.
Genomenon's top competitors include DNAnexus, Human Longevity and Denali Therapeutics.
Genomenon offers Mastermind, Cancer Knowledgebase, and Curation Services.
Genomenon has made 1 acquisition, including Boston Genetics.
Genomenon has 19 investors. Key investors include NIH, University of Michigan, HHS, Broadoak Capital Partners, and IrishAngels.
Genomenon operates through Genomenon, Inc..